Invitae Partners with Deerfield Management
Thursday, March 23, 2023
Invitae and Deerfield Management announced a partnership to advance genetics-based drug discovery and development in rare disease. This partnership will leverage genetics and clinical data from millions of patients and Deerfield's broad drug discovery and development expertise.
The partnership will harness genetic and clinical data from millions of patients tested at Invitae and Deerfield's expertise in drug discovery to address high unmet needs among rare disease patients. Moreover, this partnership has strong potential to uncover valuable patient insights and create important treatments for many currently incurable diseases.
Precision medicine offers great promise to address unmet needs of rare disease patients, but to be successful, scientists need access to focused genetic and clinical data across sizable patient populations. For rare diseases, these data are hard to find. For example, large scale genetic biobanks have been valuable for driving forward research, but they, at times, leave rare disease researchers searching for additional data on symptomatic and diverse patients.
Invitae and Deerfield aim to address notable research gaps by drawing insights from Invitae's data platform, which includes sizable cohorts of rare disease patients. The companies will collaborate to analyse data from the over 3.6 million genetic tests delivered by Invitae linked to longitudinal clinical data, strictly in accordance with patients' preferences for sharing of their data. With these data and analytics expertise, together Invitae and Deerfield will be well-suited to uncover insights needed to discover and validate novel rare disease targets.
